CLSD
Price
$3.83
Change
+$0.04 (+1.06%)
Updated
Oct 20, 11:49 AM (EDT)
Capitalization
19.84M
29 days until earnings call
Intraday Buy/Sell Signals
MGNX
Price
$1.75
Change
+$0.10 (+6.06%)
Updated
Oct 20, 12:11 PM (EDT)
Capitalization
104.29M
22 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

CLSD vs MGNX

Header iconCLSD vs MGNX Comparison
Open Charts CLSD vs MGNXBanner chart's image
Clearside Biomedical
Price$3.83
Change+$0.04 (+1.06%)
Volume$2.1K
Capitalization19.84M
MacroGenics
Price$1.75
Change+$0.10 (+6.06%)
Volume$100
Capitalization104.29M
CLSD vs MGNX Comparison Chart in %
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLSD vs. MGNX commentary
Oct 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLSD is a Hold and MGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 20, 2025
Stock price -- (CLSD: $3.79 vs. MGNX: $1.65)
Brand notoriety: CLSD and MGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLSD: 20% vs. MGNX: 62%
Market capitalization -- CLSD: $19.84M vs. MGNX: $104.29M
CLSD [@Biotechnology] is valued at $19.84M. MGNX’s [@Biotechnology] market capitalization is $104.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLSD’s FA Score shows that 0 FA rating(s) are green whileMGNX’s FA Score has 0 green FA rating(s).

  • CLSD’s FA Score: 0 green, 5 red.
  • MGNX’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLSD and MGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLSD’s TA Score shows that 5 TA indicator(s) are bullish while MGNX’s TA Score has 4 bullish TA indicator(s).

  • CLSD’s TA Score: 5 bullish, 3 bearish.
  • MGNX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CLSD is a better buy in the short-term than MGNX.

Price Growth

CLSD (@Biotechnology) experienced а -4.77% price change this week, while MGNX (@Biotechnology) price change was -2.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.35%. For the same industry, the average monthly price growth was +17.64%, and the average quarterly price growth was +72.32%.

Reported Earning Dates

CLSD is expected to report earnings on Nov 18, 2025.

MGNX is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+4.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MGNX($104M) has a higher market cap than CLSD($19.8M). MGNX YTD gains are higher at: -49.231 vs. CLSD (-73.404). CLSD has higher annual earnings (EBITDA): -16.2M vs. MGNX (-26.91M). CLSD has less debt than MGNX: CLSD (533K) vs MGNX (37.2M). MGNX has higher revenues than CLSD: MGNX (164M) vs CLSD (4.17M).
CLSDMGNXCLSD / MGNX
Capitalization19.8M104M19%
EBITDA-16.2M-26.91M60%
Gain YTD-73.404-49.231149%
P/E RatioN/AN/A-
Revenue4.17M164M3%
Total CashN/A176M-
Total Debt533K37.2M1%
FUNDAMENTALS RATINGS
CLSD vs MGNX: Fundamental Ratings
CLSD
MGNX
OUTLOOK RATING
1..100
9280
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6552
P/E GROWTH RATING
1..100
7794
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MGNX's Valuation (81) in the Biotechnology industry is in the same range as CLSD (93) in the Pharmaceuticals Major industry. This means that MGNX’s stock grew similarly to CLSD’s over the last 12 months.

MGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that MGNX’s stock grew similarly to CLSD’s over the last 12 months.

MGNX's SMR Rating (98) in the Biotechnology industry is in the same range as CLSD (100) in the Pharmaceuticals Major industry. This means that MGNX’s stock grew similarly to CLSD’s over the last 12 months.

MGNX's Price Growth Rating (52) in the Biotechnology industry is in the same range as CLSD (65) in the Pharmaceuticals Major industry. This means that MGNX’s stock grew similarly to CLSD’s over the last 12 months.

CLSD's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as MGNX (94) in the Biotechnology industry. This means that CLSD’s stock grew similarly to MGNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLSDMGNX
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
88%
Momentum
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
85%
Advances
ODDS (%)
Bullish Trend 22 days ago
83%
Bullish Trend 5 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CLSD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BLND3.320.05
+1.53%
Blend Labs
ROK347.66-0.36
-0.10%
Rockwell Automation
SON40.03-0.13
-0.32%
Sonoco Products Company
THAR2.87-0.01
-0.35%
Tharimmune Inc.
BZUN3.29-0.03
-0.90%
Baozun

CLSD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLSD has been loosely correlated with ABVX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CLSD jumps, then ABVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLSD
1D Price
Change %
CLSD100%
+2.29%
ABVX - CLSD
51%
Loosely correlated
-0.19%
NEVPF - CLSD
35%
Loosely correlated
N/A
IMNN - CLSD
30%
Poorly correlated
+0.59%
ANEB - CLSD
28%
Poorly correlated
+5.56%
MGNX - CLSD
28%
Poorly correlated
-2.37%
More

MGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGNX has been loosely correlated with RGNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MGNX jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGNX
1D Price
Change %
MGNX100%
-2.37%
RGNX - MGNX
53%
Loosely correlated
-4.94%
CRBU - MGNX
52%
Loosely correlated
-1.50%
XNCR - MGNX
51%
Loosely correlated
-1.20%
BEAM - MGNX
51%
Loosely correlated
+0.74%
IDYA - MGNX
50%
Loosely correlated
+5.67%
More